Emergence of Sentinel Node Biopsy in Breast Cancer as Standard-of-Care in Academic Comprehensive Cancer Centers
Identifieur interne : 009147 ( Main/Exploration ); précédent : 009146; suivant : 009148Emergence of Sentinel Node Biopsy in Breast Cancer as Standard-of-Care in Academic Comprehensive Cancer Centers
Auteurs : Stephen B. Edge ; Joyce C. Niland ; Michael A. Bookman ; Richard L. Theriault ; Rebecca Ottesen ; Eva Lepisto ; Jane C. WeeksSource :
- Journal of the National Cancer Institute [ 0027-8874 ] ; 2003-10-15.
Abstract
Background: Ongoing clinical trials are addressing the accuracy and safety of sentinel node biopsy (SNB) in the treatment of breast cancer; however, SNB is already increasingly being used in clinical practice. This study examined the extent and time trends of the use of SNB in stage I and II breast cancer patients. Methods: Clinical data were collected from stage I and II (tumor size ⩽5.0 cm) breast cancer patients (n = 3003) who were treated at five comprehensive cancer centers between July 1, 1997, and December 31, 2000. Axillary surgery was classified as SNB alone, SNB + axillary node dissection (AND), AND alone, or none. Patterns of use of axillary surgery were summarized as the percentage of patients receiving each surgery type. The statistical significance of time trends for the use of SNB alone was analyzed by logistic regression models. All statistical tests were two-sided. Results: Overall, SNB alone was used in 13% of patients, SNB + AND in 22%, AND alone in 59%, and no axillary surgery in 6%. Use of SNB alone was statistically significantly associated with breast-conserving surgery of both smaller (⩽2 cm) and larger tumors (2–5 cm) (P<.001 for both associations). For stage I cancer patients treated with breast-conserving surgery (n = 1763), use of SNB increased statistically significantly over the study period, from 8% in 1997 to 9%, 14%, 15%, 22%, 42%, and 58% for the next six consecutive 6-month time intervals, respectively. After controlling for center, age, and comorbidity, the odds ratio for the use of SNB alone was 2.30 (95% confidence interval = 1.88 to 2.82) for each 6-month interval (P<.001). Conclusions: Widespread use of SNB outside the clinical trial setting suggests that oncologists at cancer centers in our study have accepted SNB as standard-of-care for the treatment of breast cancer. This acceptance, if it occurs in other cancer centers and community practice, may affect accrual and generalizability of ongoing clinical trials of SNB.
Url:
DOI: 10.1093/jnci/djg076
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 006B35
- to stream Istex, to step Curation: 006B35
- to stream Istex, to step Checkpoint: 002362
- to stream Main, to step Merge: 009460
- to stream Main, to step Curation: 009147
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Emergence of Sentinel Node Biopsy in Breast Cancer as Standard-of-Care in Academic Comprehensive Cancer Centers</title><author><name sortKey="Edge, Stephen B" sort="Edge, Stephen B" uniqKey="Edge S" first="Stephen B." last="Edge">Stephen B. Edge</name></author><author><name sortKey="Niland, Joyce C" sort="Niland, Joyce C" uniqKey="Niland J" first="Joyce C." last="Niland">Joyce C. Niland</name></author><author><name sortKey="Bookman, Michael A" sort="Bookman, Michael A" uniqKey="Bookman M" first="Michael A." last="Bookman">Michael A. Bookman</name></author><author><name sortKey="Theriault, Richard L" sort="Theriault, Richard L" uniqKey="Theriault R" first="Richard L." last="Theriault">Richard L. Theriault</name></author><author><name sortKey="Ottesen, Rebecca" sort="Ottesen, Rebecca" uniqKey="Ottesen R" first="Rebecca" last="Ottesen">Rebecca Ottesen</name></author><author><name sortKey="Lepisto, Eva" sort="Lepisto, Eva" uniqKey="Lepisto E" first="Eva" last="Lepisto">Eva Lepisto</name></author><author><name sortKey="Weeks, Jane C" sort="Weeks, Jane C" uniqKey="Weeks J" first="Jane C." last="Weeks">Jane C. Weeks</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E4D3317032977033C4D5D32354E5B7FE85469E2C</idno><date when="2003" year="2003">2003</date><idno type="doi">10.1093/jnci/djg076</idno><idno type="url">https://api.istex.fr/document/E4D3317032977033C4D5D32354E5B7FE85469E2C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">006B35</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">006B35</idno><idno type="wicri:Area/Istex/Curation">006B35</idno><idno type="wicri:Area/Istex/Checkpoint">002362</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002362</idno><idno type="wicri:doubleKey">0027-8874:2003:Edge S:emergence:of:sentinel</idno><idno type="wicri:Area/Main/Merge">009460</idno><idno type="wicri:Area/Main/Curation">009147</idno><idno type="wicri:Area/Main/Exploration">009147</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Emergence of Sentinel Node Biopsy in Breast Cancer as Standard-of-Care in Academic Comprehensive Cancer Centers</title><author><name sortKey="Edge, Stephen B" sort="Edge, Stephen B" uniqKey="Edge S" first="Stephen B." last="Edge">Stephen B. Edge</name><affiliation><wicri:noCountry code="subField">MA.</wicri:noCountry></affiliation></author><author><name sortKey="Niland, Joyce C" sort="Niland, Joyce C" uniqKey="Niland J" first="Joyce C." last="Niland">Joyce C. Niland</name><affiliation><wicri:noCountry code="subField">MA.</wicri:noCountry></affiliation></author><author><name sortKey="Bookman, Michael A" sort="Bookman, Michael A" uniqKey="Bookman M" first="Michael A." last="Bookman">Michael A. Bookman</name><affiliation><wicri:noCountry code="subField">MA.</wicri:noCountry></affiliation></author><author><name sortKey="Theriault, Richard L" sort="Theriault, Richard L" uniqKey="Theriault R" first="Richard L." last="Theriault">Richard L. Theriault</name><affiliation><wicri:noCountry code="subField">MA.</wicri:noCountry></affiliation></author><author><name sortKey="Ottesen, Rebecca" sort="Ottesen, Rebecca" uniqKey="Ottesen R" first="Rebecca" last="Ottesen">Rebecca Ottesen</name><affiliation><wicri:noCountry code="subField">MA.</wicri:noCountry></affiliation></author><author><name sortKey="Lepisto, Eva" sort="Lepisto, Eva" uniqKey="Lepisto E" first="Eva" last="Lepisto">Eva Lepisto</name><affiliation><wicri:noCountry code="subField">MA.</wicri:noCountry></affiliation></author><author><name sortKey="Weeks, Jane C" sort="Weeks, Jane C" uniqKey="Weeks J" first="Jane C." last="Weeks">Jane C. Weeks</name><affiliation><wicri:noCountry code="subField">MA.</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Journal of the National Cancer Institute</title><title level="j" type="abbrev">JNCI J Natl Cancer Inst</title><idno type="ISSN">0027-8874</idno><idno type="eISSN">1460-2105</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="2003-10-15">2003-10-15</date><biblScope unit="volume">95</biblScope><biblScope unit="issue">20</biblScope><biblScope unit="page" from="1514">1514</biblScope><biblScope unit="page" to="1521">1521</biblScope></imprint><idno type="ISSN">0027-8874</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0027-8874</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Background: Ongoing clinical trials are addressing the accuracy and safety of sentinel node biopsy (SNB) in the treatment of breast cancer; however, SNB is already increasingly being used in clinical practice. This study examined the extent and time trends of the use of SNB in stage I and II breast cancer patients. Methods: Clinical data were collected from stage I and II (tumor size ⩽5.0 cm) breast cancer patients (n = 3003) who were treated at five comprehensive cancer centers between July 1, 1997, and December 31, 2000. Axillary surgery was classified as SNB alone, SNB + axillary node dissection (AND), AND alone, or none. Patterns of use of axillary surgery were summarized as the percentage of patients receiving each surgery type. The statistical significance of time trends for the use of SNB alone was analyzed by logistic regression models. All statistical tests were two-sided. Results: Overall, SNB alone was used in 13% of patients, SNB + AND in 22%, AND alone in 59%, and no axillary surgery in 6%. Use of SNB alone was statistically significantly associated with breast-conserving surgery of both smaller (⩽2 cm) and larger tumors (2–5 cm) (P<.001 for both associations). For stage I cancer patients treated with breast-conserving surgery (n = 1763), use of SNB increased statistically significantly over the study period, from 8% in 1997 to 9%, 14%, 15%, 22%, 42%, and 58% for the next six consecutive 6-month time intervals, respectively. After controlling for center, age, and comorbidity, the odds ratio for the use of SNB alone was 2.30 (95% confidence interval = 1.88 to 2.82) for each 6-month interval (P<.001). Conclusions: Widespread use of SNB outside the clinical trial setting suggests that oncologists at cancer centers in our study have accepted SNB as standard-of-care for the treatment of breast cancer. This acceptance, if it occurs in other cancer centers and community practice, may affect accrual and generalizability of ongoing clinical trials of SNB.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Bookman, Michael A" sort="Bookman, Michael A" uniqKey="Bookman M" first="Michael A." last="Bookman">Michael A. Bookman</name><name sortKey="Edge, Stephen B" sort="Edge, Stephen B" uniqKey="Edge S" first="Stephen B." last="Edge">Stephen B. Edge</name><name sortKey="Lepisto, Eva" sort="Lepisto, Eva" uniqKey="Lepisto E" first="Eva" last="Lepisto">Eva Lepisto</name><name sortKey="Niland, Joyce C" sort="Niland, Joyce C" uniqKey="Niland J" first="Joyce C." last="Niland">Joyce C. Niland</name><name sortKey="Ottesen, Rebecca" sort="Ottesen, Rebecca" uniqKey="Ottesen R" first="Rebecca" last="Ottesen">Rebecca Ottesen</name><name sortKey="Theriault, Richard L" sort="Theriault, Richard L" uniqKey="Theriault R" first="Richard L." last="Theriault">Richard L. Theriault</name><name sortKey="Weeks, Jane C" sort="Weeks, Jane C" uniqKey="Weeks J" first="Jane C." last="Weeks">Jane C. Weeks</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009147 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009147 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:E4D3317032977033C4D5D32354E5B7FE85469E2C
|texte= Emergence of Sentinel Node Biopsy in Breast Cancer as Standard-of-Care in Academic Comprehensive Cancer Centers
}}
| This area was generated with Dilib version V0.6.31. |  |